Method of inhibiting osteoclast activity
AssigneeImmunex Corporation
InventorsDirk M. ANDERSON, Laurent J. GALIBERT
Life of this patent
Estimating the term…
Abstract
Methods for inhibiting osteoclastogenesis by administering a soluble RANK polypeptide are disclosed. Such methods can be used to treat a variety of different cancers, including bone cancer, multiple myeloma, melanoma, breast cancer, squamous cell carcinoma, lung cancer, prostate cancer, hematologic cancers, head and neck cancer and renal cancer.
Claims12
A method of regulating osteoclast activity, the method comprising causing a soluble RANK to bind RANKL.
A method of ameliorating effects of excess bone loss, comprising administering a soluble RANK polypeptide composition to an individual at risk for excess bone loss, and allowing the soluble RANK to bind RANKL and inhibit binding thereof to cells expressing RANK.
Dependencies are inferred from the claim text.